Eton Pharmaceuticals Inc (ETON)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.84B
Last updated: Nov 17, 2026 at 4:30 PM ET
Eton Pharmaceuticals Inc (ETON) Stock Chart
Eton Pharmaceuticals (ETON) has a latest price of $63.65 on Nov 17, 2026, 9.9% below its 52-week high of $70.64. Its price rose 275.7% over the past 12 months. The month-end price rose 805.9% over the 5 years through Oct 2026, a compound annual rate of 55.4%.
Price Chart
From Nov 2018 to Oct 2026, its highest month-end close was $60.44 in Aug 2026 and its lowest $2.10 in Sep 2022, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ETON with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ETON.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 3.5%, and over 6 months it rose 93.5%. The month-end price rose 1,136.5% over the 3 years through Oct 2026, a compound annual rate of 131.2%.
| Period | Change |
|---|---|
| 1 month | +29.3% |
| 3 months | +3.5% |
| 6 months | +93.5% |
| 12 months | +275.7% |
| 12 months, with dividends | +275.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +1,136.5% | +131.2% |
| 5 years | +805.9% | +55.4% |
Price by Year
Its best calendar year was 2024, when the price rose 204.1%, and its weakest was 2021, when it fell 47.2%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $52.18 | +208.6% |
| 2025 | $16.91 | +27.0% |
| 2024 | $13.32 | +204.1% |
| 2023 | $4.38 | +55.3% |
| 2022 | $2.82 | -34.3% |
| 2021 | $4.29 | -47.2% |
| 2020 | $8.13 | +12.9% |
| 2019 | $7.20 | +17.6% |
Trading Range
The price is 14.8% above its 50-day average of $55.46 and 66.0% above its 200-day average of $38.34.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $63.65 | |
| 52-week high | $70.64 | -9.9% |
| 52-week low | $14.27 | +346.0% |
| 50-day average | $55.46 | +14.8% |
| 200-day average | $38.34 | +66.0% |
Price Risk
Over 3 years, its largest fall from a peak was 39.2%.
| Measure | Value |
|---|---|
| 1-year beta | 0.56 |
| Largest fall, 1 year | -26.8% |
| Largest fall, 3 years | -39.2% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ETON
What is ETON's 1-year price change?
Eton Pharmaceuticals's price rose 275.7% over the past 12 months. With dividends included, the 12-month total return was 275.7%.
What is ETON's 5-year price change?
Eton Pharmaceuticals's month-end price rose 805.9% over the 5 years through Oct 2026, a compound annual rate of 55.4%. These figures leave out dividends.
What is ETON's 52-week high and low?
Eton Pharmaceuticals's 52-week high is $70.64 and its 52-week low is $14.27. Its latest price of $63.65 on Nov 17, 2026 is 9.9% below the high.
What is ETON's beta?
Eton Pharmaceuticals's 1-year beta against the S&P 500 is 0.56, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 26.8%.
Is the ETON chart free?
Yes. Advanced Charting for ETON is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ETON pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors